Akero Therapeutics Alpha and Beta Analysis
| AKRODelisted Stock | USD 54.65 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Akero Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Akero Therapeutics over a specified time horizon. Remember, high Akero Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Akero Therapeutics' market risk premium analysis include:
Beta (0.08) | Alpha 0.33 | Risk 0.14 | Sharpe Ratio 0.32 | Expected Return 0.0444 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Akero |
Akero Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Akero Therapeutics market risk premium is the additional return an investor will receive from holding Akero Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Akero Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Akero Therapeutics' performance over market.| α | 0.33 | β | -0.08 |
Akero Therapeutics Fundamentals Vs Peers
Comparing Akero Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Akero Therapeutics' direct or indirect competition across all of the common fundamentals between Akero Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Akero Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Akero Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Akero Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Akero Therapeutics to competition |
| Fundamentals | Akero Therapeutics | Peer Average |
| Return On Equity | -0.35 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Current Valuation | 3.76 B | 16.62 B |
| Shares Outstanding | 82.32 M | 571.82 M |
| Shares Owned By Insiders | 1.45 % | 10.09 % |
| Shares Owned By Institutions | 98.55 % | 39.21 % |
| Number Of Shares Shorted | 4.32 M | 4.71 M |
Akero Therapeutics Opportunities
Akero Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Is Akero Therapeutics Stock Outpacing Its Medical Peers This Year | 10/01/2025 |
2 | Akero Therapeutics CEO Andrew Cheng Sells 30,000 Shares | 10/15/2025 |
3 | Disposition of 4284 shares by Young Jonathan of Akero Therapeutics at 21.09 subject to Rule 16b-3 | 11/24/2025 |
4 | Akero Therapeutics shareholders approve acquisition by Novo Nordisk - Investing.com | 12/03/2025 |
About Akero Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Akero or other delisted stocks. Alpha measures the amount that position in Akero Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Akero Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Akero Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akero Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Akero Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Akero Therapeutics. Please utilize our Beneish M Score to check the likelihood of Akero Therapeutics' management manipulating its earnings.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Akero Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Akero Stock
If you are still planning to invest in Akero Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Akero Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |